The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Müller cell‐derived VEGF is a significant contributor to retinal neovascularization
Abstract
Vascular endothelial growth factor (VEGF‐A) is a major pathogenic factor and a therapeutic target for age‐related macular degeneration, diabetic retinopathy, and retinopathy of prematurity. Despite intensive effort in the field, the cellular mechanisms of VEGF action remain virtually uninvestigated. This situation makes it difficult to design cellular target‐based therapeutics for these diseases. In light of the recent finding that VEGF is a potential neurotrophic factor, revealing the cellular mechanisms of VEGF action becomes necessary to preserve its beneficial effect and inhibit its pathological function in long‐term anti‐VEGF therapeutics for ocular vascular diseases. We therefore generated conditional VEGF knockout mice with an inducible Cre/ lox system and determined the significance of Müller cell‐derived VEGF in retinal development and maintenance and ischaemia‐induced neovascularizartion and vascular leakage. Retinal development in the conditional VEGF knockout mice was analysed by examining retinal and choroidal vasculatures and retinal morphology and function. Ischaemia‐induced retinal neovascularization and vascular leakage in the conditional VEGF knockout mice were analysed with fluorescein angiography, quantification of proliferative neovascular cells, immunohistochemistry, and immunoblotting using an oxygen‐induced retinopathy model. Our results demonstrated that disruption of Müller cell‐derived VEGF resulted in no apparent defects in retinal and choroidal vasculatures and retinal morphology and function, significant inhibition of the ischaemia‐induced retinal neovascularization and vascular leakage, and attenuation of the ischaemia‐induced breakdown of the blood‐retina barrier. These results suggest that the retinal Müller cell‐derived VEGF is a major contributor to ischaemia‐induced retinal vascular leakage and pre‐retinal and intra‐retinal neovascularization. The observation that a significant, but not complete, reduction of VEGF in the retina does not cause detectable retinal degeneration suggests that appropriate doses of anti‐VEGF agents may be important to the safe treatment of retinal vascular diseases. Copyright © 2009 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
FRANK, R. N., AMIN, R. H., ELIOTT, D., PUKLIN, J. E., & ABRAMS, G. W. (1996) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(14)72066-5 · Cited by 366
Inducible Expression of Cre Recombinase in the Retinal Pigmented Epithelium
Le, Y.-Z., Zheng, W., Rao, P.-C., Zheng, L., Anderson, R. E., Esumi, N., Zack, D. J., & Zhu, M. (2008) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.07-1105 · Cited by 79
Self-citation
Cited by
Antonetti, D. A., Klein, R., & Gardner, T. W. (2012) · New England Journal of Medicine · doi:10.1056/nejmra1005073 · Cited by 1,659
Neurodegeneration in the diabetic eye: new insights and therapeutic perspectives
Simó, R., & Hernández, C. (2014) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2013.09.005 · Cited by 490
The Role of Inflammation in Diabetic Retinopathy
Forrester, J. V., Kuffova, L., & Delibegovic, M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.583687 · Cited by 432
Müller Cell-Derived VEGF Is Essential for Diabetes-Induced Retinal Inflammation and Vascular Leakage
Wang, J., Xu, X., Elliott, M. H., Zhu, M., & Le, Y.-Z. (2010) · Diabetes · doi:10.2337/db09-1420 · Cited by 396
Self-citationLee, C., Kim, M.-J., Kumar, A., Lee, H.-W., Yang, Y., & Kim, Y. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02249-0 · Cited by 365
Retinal vasculature development in health and disease
Selvam, S., Kumar, T., & Fruttiger, M. (2018) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2017.11.001 · Cited by 353
Pathophysiology and Mechanisms of Severe Retinopathy of Prematurity
Hartnett, M. E. (2015) · Ophthalmology · doi:10.1016/j.ophtha.2014.07.050 · Cited by 351
Animal models of choroidal and retinal neovascularization
Grossniklaus, H. E., Kang, S. J., & Berglin, L. (2010) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2010.05.003 · Cited by 350
Müller cells and diabetic retinopathy
Coughlin, B. A., Feenstra, D. J., & Mohr, S. (2017) · Vision Research · doi:10.1016/j.visres.2017.03.013 · Cited by 332
Familial exudative vitreoretinopathy and related retinopathies
Gilmour, D. F. (2015) · Eye · doi:10.1038/eye.2014.70 · Cited by 294
Wang, X., Fan, W., Li, N., Ma, Y., Yao, M., Wang, G., He, S., Li, W., Tan, J., Lu, Q., et al. (2023) · Genome Biology · doi:10.1186/s13059-023-02931-y · Cited by 288
Simó, R., Sundstrom, J. M., & Antonetti, D. A. (2014) · Diabetes Care · doi:10.2337/dc13-2002 · Cited by 280
From oxygen to erythropoietin: Relevance of hypoxia for retinal development, health and disease
Caprara, C., & Grimm, C. (2012) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2011.11.003 · Cited by 176
Liu, X., Zhang, B., McBride, J. D., Zhou, K., Lee, K., Zhou, Y., Liu, Z., & Ma, J.-X. (2013) · Diabetes · doi:10.2337/db12-1710 · Cited by 53
Self-citation(2016) · Europe PMC (PubMed Central) · Cited by 51
ERK1/2 signaling pathway in the release of VEGF from Müller cells in diabetes
Ye, X., Ren, H., Zhang, M., Sun, Z., Jiang, A. C., & Xu, G. (2012) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.11-9076 · Cited by 44
Zhou, L., Xu, Z., Oh, Y., Gamuyao, R., Lee, G., Xie, Y., Cho, H., Lee, S., & Duh, E. J. (2021) · JCI Insight · doi:10.1172/jci.insight.93382 · Cited by 34
Metadata
- Authors
- Bai, Y., Ma, J., Guo, J., Wang, J., Zhu, M., Chen, Y., & Le, Y.
- Venue
- The Journal of Pathology
- Publisher
- Wiley
- Published
- 2009-09-18
- Volume
- 219
- Issue
- 4
- Pages
- 446-454
- ISSN
- 0022-3417 (ISSN-L)
- 1096-9896
- OpenAlex
- W2038609067
- Cited by
- 238
- References
- 2
- FWCI
- 9.50
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.